Skip to main content

Genetically engineered goats could be the key to mass-producing cancer drugs

Could the answer to mass-producing cancer drugs be … genetically modified goats? It might sound kind of crazy, but upon closer inspection, it actually makes a whole lot of sense. The drugs in question, therapeutic mAbs (aka monoclonal antibodies), are used in the treatment of human diseases including cancer. They are commonly produced in large bioreactors using cultured cells from mammals. But this process is extremely expensive, which in turn raises the cost for customers who may desperately need the drugs.

An international team of researchers led by Goetz Laible, a a senior scientist for New Zealand-based AgResearch and an animal scientist at the University of Auckland, is setting out to make these drugs in a different way — by using genetically engineered goats to produce them in their milk.

“To generate goats that are capable of producing the mAb in their milk, we first introduced the genes holding the information for the mAb into the genome of goat cells,” Laible told Digital Trends. “From such goat cells, live goats were generated using the cloning technology that was developed to generate the sheep Dolly. With these additional genes in their genomes, the goats were able to produce the antibody in their milk — but were otherwise normal, healthy animals.”

Goetz-and-goats
Goetz and his goats. Goetz Laible

This is not the first time that genetically engineered goats have been used as unlikely manufacturing vessels in the name of science. In 2012, scientists tested the idea of using goats for the production of spider silk in large quantities.

Laible said that this latest study validates the idea that goats could serve as an “excellent platform” for large-scale production of cancer-treatment drugs at a lower cost. In the process, it could help make the drugs, which are used for the treatment of a wide range of human diseases, available more widely. It may also have additional benefits.

“The scale of production is essentially fixed [at present due to ] the size of the bioreactor for mammalian cell cultures, and scaling of production volumes is very limited,” he said. “By contrast, an animal production platform is very flexible. Production volumes can be readily scaled by simply increasing or decreasing the number of production animals.”

The team now plans to undertake additional testing to further demonstrate the safety and effectiveness of anti-cancer treatments manufactured using goats.

A paper describing the research is available to read via the biology preprint server bioRxix.

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
A surprising new competitor to Google Docs just made its debut
The Proton Mail email app running on an iPad.

Proton, known for its popular email client, has always made it clear that it takes user privacy seriously. And that's the defining feature of a new piece of software in its lineup calle dProton Docs, which the company announced in a blog post on Wednesday.

The latest addition launching today promises to push the envelope and encrypt the file, cursor movements, and keystrokes.

Read more
AMD didn’t even need its best CPU to beat Intel
A render of a Ryzen 9000 CPU.

Looks like the competition between AMD and Intel is about to start heating up again. AMD's upcoming second-best processor, the Ryzen 9 9900X, was just spotted in an early benchmark -- and the results are shockingly good. If this is what AMD can do with a 12-core CPU, what's going to happen when the 16-core version of Zen 5 appears in tests?

The happy news (for AMD fans, at least) comes directly from the Geekbench 6.2 database, and it all comes down to a benchmark of what appears to be a retail sample of the Ryzen 9 9900X. The chip scored an impressive 3,401 points in the single-core score, and 19,756 points in the multi-core score. That puts it far above its predecessor, the Ryzen 9 7900X, but that's not its only success.

Read more
AMD is now more recognizable than Intel
AMD's CEO delivering the Computex 2024 presentation.

While many would assume otherwise, a recent report tells us that AMD is now a more recognizable brand than Intel -- and that's big news for the tech giant. Kantar's BrandZ Most Valuable Brands report ranks AMD at 41, followed by Intel at number 48. Beating its long-standing rival is just one part of the prize for AMD. It also ranked among the top 10 risers in the report, meaning that its brand value increased a lot over the last year.

According to the report, AMD saw massive brand growth since 2023, increasing by 53% year-over-year. Moreover, AMD's brand value reached $51.86 million in the Business Technology and Services Platforms category. It's easy to guess where that intense growth is coming from -- AMD is leaning into AI, just like its rivals Intel and Nvidia have done in recent years.

Read more